Related Experiment Video

Updated: May 20, 2025

Comprehensive Protocol to Sample and Process Bone Marrow for Measuring Measurable Residual Disease and Leukemic Stem Cells in Acute Myeloid Leukemia
09:57

Comprehensive Protocol to Sample and Process Bone Marrow for Measuring Measurable Residual Disease and Leukemic Stem Cells in Acute Myeloid Leukemia

Published on: March 5, 2018

29.1K

Multicenter Retrospective Evaluation of Treatment for High-Risk Acute Promyelocytic Leukemia: Real-World Outcomes

Lydia L Benitez1, Kayleigh R Marx2, Caitlin R Rausch2

  • 1University of Michigan College of Pharmacy, Michigan Medicine, Ann Arbor, Michigan, USA.

American Journal of Hematology
|March 26, 2025
PubMed

Estimated 36-month Survival Comparison between ATRA/ATO/GO and APML4 regimens.

Keywords:
ATRAarsenicgemtuzumab ozogamicinhigh risk APL

More Related Videos

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia10:49

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia

Published on: September 18, 2013

18.1K
Enumeration of Major Peripheral Blood Leukocyte Populations for Multicenter Clinical Trials Using a Whole Blood Phenotyping Assay14:45

Enumeration of Major Peripheral Blood Leukocyte Populations for Multicenter Clinical Trials Using a Whole Blood Phenotyping Assay

Published on: September 16, 2012

14.9K

Related Concept Videos

Hazard Ratio01:12

Hazard Ratio

The hazard ratio (HR) is a widely used measure in clinical trials to compare the risk of events, such as death or disease recurrence, between two groups over time. It reflects the ratio of hazard rates—the instantaneous risk of the event occurring—between a treatment group and a control group. This measure provides valuable insights into the relative effectiveness of a treatment by assessing how the risk of an event differs between the two groups.
For example, in a clinical trial...
72